Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
Clinical trial NCT04270864 · TERMINATED
Trial details
- NCT number
- NCT04270864
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-10
- Primary completion
- 2021-07-13
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.